Category: Novo Nordisk
-
Delhi High Court allows Dr. Reddy’s to enter Indian semaglutide market in March 2026, dismisses Novo Nordisk appeal
In a landmark judgment, the Delhi High Court has ruled that Novo Nordisk failed to prove why it should be granted an interim injunction against Dr. Reddy’s, but has ordered the latter not to proceed with sales in Indian until the patent-in-suit expires on March 20, 2026.
-
PI spate: Novo Nordisk just obtained 29 injunctions (26 over patent, 3 over UCL) against semaglutide rivals in Germany, served at CPHI fair
Context: What’s new: Novo Nordisk has just obtained, served and enforced a whopping 29 preliminary injunctions (PIs) against (mostly Asian and to a lesser extent European) companies offering the active pharmaceutical ingredient semaglutide and/or pharmaceuticals containing semaglutide at the CPHI fair. The pan-European law firm of Hoyng Rokh Monegier, in collaboration with UK firm Bristows,…